Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.46 |
| ▸ | CHRNA10 | Q9GZZ6 | 8/20 | 0.46 |
| ▸ | CHRNA9 | Q9UGM1 | 8/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3312230 | 0.99 | CHRNA7 (0.47) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| SCHEMBL13334053 | 0.91 | NPC1 (0.49) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| Bromide SCHEMBL3317318 | 0.90 | NPC1 (0.51) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| SCHEMBL4401493 | 0.90 | CHRNA7 (0.46) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| SCHEMBL4400594 | 0.88 | NPC1 (0.42) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| SCHEMBL13334226 | 0.84 | NPC1 (0.65) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| Bromide SCHEMBL3313498 | 0.83 | NPC1 (0.68) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| SCHEMBL4400673 | 0.82 | NPC1 (0.45) | CHRNA7CHRNA10CHRNA9NPC1RAB9A | |
| SCHEMBL13334116 | 0.82 | HTT (0.43) | NPC1RAB9APOLBSMN1; SMN2 | |
| Bromide SCHEMBL3307928 | 0.81 | HTT (0.42) | CHRNA7CHRNA10CHRNA9NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550753-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | disclosed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHRNA7 8/4885CHRNA10 4/4885CHRNA9 13/4885 |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHRNA7 8/4885CHRNA10 4/4885CHRNA9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.